This week on “The Top Line,” we explore the European biotech investment landscape. 

Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. 

To learn more about the topics in this episode: 
'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023
'Optimism' at Jefferies conference, but don't expect biotech IPO boost soon, says Sofinnova chair

This week on “The Top Line,” we explore the European biotech investment landscape. 
Fierce Biotech’s James Waldron sits down with Maina Bhaman, a Partner at Sofinnova Capital Strategy, who provides insights into how investors are approaching the European biotech sector. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercebiotech.com/biotech/fundamentals-are-really-strong-why-investors-are-staying-loyal-european-biotech-2023">'The fundamentals are really strong': Why investors are staying loyal to European biotech in 2023</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/optimism-jefferies-conference-dont-expect-biotech-ipo-boost-next-year-says-sofinova-chair">'Optimism' at Jefferies conference, but don't expect biotech IPO boost soon, says Sofinnova chair</a></li>
</ul>

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&D and device development. Available every Friday morning. 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech, and Fierce Pharma recount the latest industry trends and why they matter. We'll analyze the week's biggest business news, from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.&nbsp;

The Top Line

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We’ll analyze the week’s biggest business news—from mergers and marketing to drug R&D and device development. Available every Friday morning.

 

Biopharma and medtech explained. Every week, journalists from Fierce Biotech, Fierce Medtech and Fierce Pharma recount the latest industry trends and why they matter. We&rsquo;ll analyze the week&rsquo;s biggest business news&mdash;from mergers and marketing to drug R&amp;D and device development. Available every Friday morning.
&nbsp;

A closer look at European biotech investment in 2024

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023.  

This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy break down the numbers, highlight key trends and share some of the biggest changes at the top and bottom of the rankings year over year.  

To learn more about the topics in this episode:  
The top 20 pharma companies by 2023 revenue
The top 20 pharma companies by 2022 revenue

Fierce Pharma publishes a yearly special report highlighting the top 20 pharmas based on their revenue. The most recent edition, published this month, ranks each pharma based on their total revenues for 2023.  
This week on "The Top Line," Fierce Pharma Senior Editor Eric Sagonowsky and Senior Writer Kevin Dunleavy break down the numbers, highlight key trends and share some of the biggest changes at the top and bottom of the rankings year over year.  
To learn more about the topics in this episode:  
<ul>
<li><a href="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2023-revenue" data-cke-saved-href="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2023-revenue">The top 20 pharma companies by 2023 revenue</a></li>
<li><a href="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2022-revenue" data-cke-saved-href="https://www.fiercepharma.com/pharma/top-20-pharma-companies-2022-revenue">The top 20 pharma companies by 2022 revenue</a></li>
</ul>

A look at pharma revenue rankings

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. We're diving into our recent spin on March Madness at Fierce.

This time around, Fierce Biotech kicked off its inaugural Best Biotech Name tournament, while over at Fierce Pharma Marketing, we held our biannual Drug Names tournament.

The editors discuss what makes a company or drug name tick, what to steer clear of, and how the entire competition played out. 

To learn more about the topics in this episode: 
#FierceMadness: AstraZeneca and Ionis cruise to victory as Wainua trounces Lilly's Mounjaro for the tournament win
#FierceMadness: The Best Biotech Name Tournament—A champion is CROWNED

This week on “The Top Line,” we're joined by Fierce Biotech Senior Editor Annalee Armstrong and Fierce Pharma Marketing Senior Editor Ben Adams. We're diving into our recent spin on March Madness at Fierce.
This time around, Fierce Biotech kicked off its inaugural Best Biotech Name tournament, while over at Fierce Pharma Marketing, we held our biannual Drug Names tournament.
The editors discuss what makes a company or drug name tick, what to steer clear of, and how the entire competition played out. 
To learn more about the topics in this episode: 
<ul>
<li><a href="https://www.fiercepharma.com/marketing/fierce-madness-back-get-voting-2024-drug-name-tournament" data-cke-saved-href="https://www.fiercepharma.com/marketing/fierce-madness-back-get-voting-2024-drug-name-tournament">#FierceMadness: AstraZeneca and Ionis cruise to victory as Wainua trounces Lilly's Mounjaro for the tournament win</a></li>
<li><a href="https://www.fiercebiotech.com/biotech/fierce-madness-best-biotech-name-championship-2024" data-cke-saved-href="https://www.fiercebiotech.com/biotech/fierce-madness-best-biotech-name-championship-2024">#FierceMadness: The Best Biotech Name Tournament—A champion is CROWNED</a></li>
</ul>

Winning formulas for the best biotech and drug names

Jeff Beck of BioCare is in the hotseat for this edition of The Top Line.

Beck is the Chief Development Officer at the company, which stands tall as a pioneer in specialty product distribution with over 40 years of experience dating back to hemophilia therapies.

During the conversation, Beck provides an inside look at the rapidly evolving specialty distribution landscape. He outlines how the patient-centric model is working well and is supported by efficient supply chains. However, the future will demand increasing personalization to handle a wider range of complex product archetypes like cell and gene therapies. This, Beck says, calls for expanded data capabilities around inventory visibility, site analytics and dissecting the patient journey.

Beck also goes on to explain how new regulations like the Inflation Reduction Act will impact specialty distribution, and why emerging manufacturers will increasingly rely on experienced partners like BioCare.

Don't miss this insightful discussion on meeting today's specialty distribution needs while paving the way for tomorrow's innovations.

Tune in now.

Jeff Beck of BioCare is in the hotseat for this edition of The Top Line.
Beck is the Chief Development Officer at the company, which stands tall as a pioneer in specialty product distribution with over 40 years of experience dating back to hemophilia therapies.
During the conversation, Beck provides an inside look at the rapidly evolving specialty distribution landscape. He outlines how the patient-centric model is working well and is supported by efficient supply chains. However, the future will demand increasing personalization to handle a wider range of complex product archetypes like cell and gene therapies. This, Beck says, calls for expanded data capabilities around inventory visibility, site analytics and dissecting the patient journey.
Beck also goes on to explain how new regulations like the Inflation Reduction Act will impact specialty distribution, and why emerging manufacturers will increasingly rely on experienced partners like BioCare.
Don't miss this insightful discussion on meeting today's specialty distribution needs while paving the way for tomorrow's innovations.
Tune in now.

Jeff Beck of BioCare offers his insight on patient-centric models, complex therapies, data needs, seamless product access and much more.

A closer look at European biotech investment in 2024

In 1 playlist(s)

The Top Line

Social links

Follow podcast

Recent clips